Cited by 10Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsSingle-cell and spatial transcriptomics

Loss of Inpp5d has disease‐relevant and sex‐specific effects on glial transcriptomes

Open access
Dabin, Luke C., Kersey, Holly, Kim, Byungwook, Acri, Dominic J., Sharify, Daniel, Lee‐Gosselin, Audrey, Lasagna‐Reeves, Cristian A., Oblak, Adrian L. +2 more·2024·Alzheimer's & Dementia

Abstract

INTRODUCTION: Inpp5d is genetically associated with Alzheimer's disease risk. Loss of Inpp5d alters amyloid pathology in models of amyloidosis. Inpp5d is expressed predominantly in microglia but its function in brain is poorly understood. METHODS: We performed single‐cell RNA sequencing to study the effect of Inpp5d loss on wild‐type mouse brain transcriptomes. RESULTS: Loss of Inpp5d has sex‐specific effects on the brain transcriptome. Affected genes are enriched for multiple neurodegeneration terms. Network analyses reveal a gene co‐expression module centered around Inpp5d in female mice. Inpp5d loss alters Pleotrophin (PTN), Prosaposin (PSAP), and Vascular Endothelial Growth Factor A (VEGFA) signaling probability between cell types. DISCUSSION: Our data suggest that the normal function of Inpp5d is entangled with mechanisms involved in neurodegeneration. We report the effect of Inpp5d loss without pathology and show that this has dramatic effects on gene expression. Our study provides a critical reference for researchers of neurodegeneration, allowing separation of disease‐specific changes mediated by Inpp5d in disease from baseline effects of Inpp5d loss. Highlights: Loss of Inpp5d has different effects in male and female mice. Genes dysregulated by Inpp5d loss relate to neurodegeneration. Total loss of Inpp5d in female mice collapses a conserved gene co‐expression module. Loss of microglial Inpp5d affects the transcriptome of other cell types.

AI snapshot

Written from the paper’s full text.

TL;DR

In wild-type mice, loss of *Inpp5d* causes sex-specific and cell-type-specific transcriptomic changes, with female *Inpp5d*−/− mice showing far more differentially expressed genes and collapse of an *Inpp5d*-centered microglial co-expression module. The authors provide a baseline single-cell resource for separating *Inpp5d* effects from amyloid pathology.

Key findings

  • Female *Inpp5d*−/− mice had 2,874 DEGs, almost three times more than any other comparison; 137 DEGs overlapped across all comparisons, and all overlapping DEG lists were enriched for KEGG neurodegeneration terms including Parkinson disease, amyotrophic lateral sclerosis, Alzheimer's disease, prion disease, pathways of neurodegeneration, and Huntington disease.
  • hdWGCNA identified a female microglial module (Female-1) of 5,056 genes with *Inpp5d* as the most central gene; its eigenvalue was dramatically reduced in *Inpp5d*−/− microglia. A male microglial module existed but *Inpp5d* was less central (256/5,798) and showed no notable eigenvalue change by genotype.
  • CellChat inferred decreased total interactions in female mice from wild-type (203) to heterozygous (195) to homozygous knockout (70), with interaction strength falling from 8.279/8.384 to 2.154. In male mice, interactions increased from 246/207 to 359 and strength from 6.331/6.482 to 10.628. PTN signaling decreased and PSAP/VEGFA signaling increased in both sexes, while NCAM1 astrocyte communication changed in opposite directions by sex.
  • Cluster proportions differed by sex for M1 (p = 4.4 × 10−3), M2 (p = 0.0348), and M3 (p = 8.4 × 10−3); male *Inpp5d*−/− mice showed decreased M1 (p = 0.0129), male *Inpp5d*+/− mice showed increased M3 (p = 0.0323), and homozygous loss increased microglial cluster 4 (p = 0.039).

Methods

  • Single-cell RNA sequencing was performed on 6-week-old C57BL/6J wild-type, *Inpp5d*+/−, and *Inpp5d*−/− mice, with two males and two females per genotype (total n = 12), using a custom neuron-depleting dissociation protocol, myelin removal, and 10x Genomics Chromium Next GEM Single Cell 3′ v3.1; 57,742 cells passed quality control.
  • Data were processed with CellRanger v4.0.0, SoupX, DoubletFinder, and Seurat/SCTransform; clustering used 26 principal components overall, 22 for female and 25 for male datasets, with annotation by scMCA.
  • Differential expression used Wilcoxon rank-sum tests with Bonferroni adjustment; hdWGCNA and CellChat were run on merged astrocyte, endothelial, microglia, and oligodendrocyte clusters.

Limitations

  • The paper states that sample size was reduced to n = 2 per genotype and sex, and that high variance in cluster proportions for M1 and M3 made the authors hesitant to draw firm conclusions from those distributions; it also notes that cross-study comparisons are difficult because prior *Inpp5d* studies used differing methodologies.
  • Evident from the text: mice were analyzed only at 6 weeks because homozygous knockouts are not viable after 7–12 weeks, and no amyloid/pathology model was used, so findings represent baseline effects before disease onset.
  • Evident from the text: CellChat signaling changes are inferred from ligand–receptor expression rather than experimentally validated, and hdWGCNA modules are co-expression associations rather than causal relationships.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/alz.13901

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

26 of 34 cited sources checked · 13 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    Inpp5d is expressed predominantly in microglia in the brain.

    “Inpp5d is expressed predominantly in microglia but its function in brain is poorly understood.”
    • Also stated in: § INTRODUCTION · hedged
      “In the brain, Inpp5d is thought to be expressed mainly in microglia”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [16] Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015; 77: 43‐ 51. 24951455 PMC4234692 source

      The Immune Response > CD33 section discusses microglial expression of CD33, not INPP5D. Searches of our full-text copy for INPP5D and SHIP1 found no passage addressing whether INPP5D is expressed predominantly in brain microglia; page numbers were unavailable. (LLM, conf=0.75)

      Experimental — accuracy not yet measured
  • Premisecitation

    Loss of Inpp5d alters amyloid pathology in models of amyloidosis.

    “Loss of Inpp5d alters amyloid pathology in models of amyloidosis.”
    • Also stated in: § INTRODUCTION · plain
      “Recent research has revealed that Inpp5d was upregulated in amyloid plaque–associated microglia in 5XFAD models of familial AD and that ablation of Inpp5d in these mice reduced amyloid pathology.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [17] Tsai AP, Lin PB‐C, Dong C, et al. INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque‐associated microglia. Neurobiol Dis. 2021; 153: 105303. 33631273 PMC8082515 source

      The Results section reports increased Inpp5d expression in 5xFAD mice, not the effect of losing Inpp5d on amyloid pathology. The Discussion says findings from an Inpp5d-inactivated mouse model will help determine its role in disease progression; the Conclusions likewise place loss-of-function effects in future studies. Searches for loss of Inpp5d and amyloid pathology found no reported outcome. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [18] Lin PB‐C, Tsai APo‐Yi, Soni D, et al. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2528‐ 2537. doi: 10.1002/alz.12849 36524682 source

      The Abstract reports that Inpp5d haplodeficiency increased amyloid plaque clearance in 5xFAD mice, supporting an effect on amyloid pathology. The claim says “models” of amyloidosis, but the paper reports this finding in one model, 5xFAD. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [19] Castranio EL, Hasel P, Haure‐Mirande J‐V, et al. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2239‐ 2252. doi: 10.1002/alz.12821 36448627 PMC10481344 source
  • Findingcitation

    M7 shows high expression of activation marker Tyrobp.

    “whereas M7 shows high expression of activation marker Tyrobp. 36 , 37 , 38”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites [36] Murai N, Mitalipova M, Jaenisch R. Functional analysis of CX3CR1 in human induced pluripotent stem (iPS) cell‐derived microglia‐like cells. Eur J Neurosci. 2020; 52: 3667‐ 3678. 32579729 PMC8168698 source

      The Results section on activation markers identifies TNFα, IL-6, IL-1β, CD206, IL-4 and ARG1, but does not discuss Tyrobp or M7. Searches for the quoted phrase and for Tyrobp with M7 found no passage addressing the claimed expression pattern; page numbers were unavailable in our copy. (LLM, conf=0.75)

      Experimental — accuracy not yet measured
    • cites [37] Morillas AG, Besson VC, Lerouet D. Microglia and neuroinflammation: what place for p2ry12? Int J Mol Sci. 2021; 22: 1‐ 16. PMC7915979 33561958 source

      Section 2.4 discusses P2RY12 as a marker of healthy microglia and its decrease during activation; section 4 discusses microglial activation states. Neither addresses an M7 population or Tyrobp expression. Searches for “M7 Tyrobp” and “Tyrobp activation marker microglial cluster M7” found no passage supporting the claim; page numbers were not available in our copy. (LLM, conf=0.73)

      Experimental — accuracy not yet measured
    • cites [38] Audrain M, Haure‐Mirande J‐V, Mleczko J, et al. Reactive or transgenic increase in microglial TYROBP reveals a TREM2‐independent TYROBP–APOE link in wild‐type and Alzheimer's‐related mice. Alzheimer's Dement. 2021; 17: 149‐ 163. 33314529 PMC7938663 source

      The Results (Figure 1) report increased Tyrobp expression in recruited microglia, supporting the expression part of the claim. Our copy does not identify an M7 population or show that M7 has high Tyrobp expression. The Results also distinguish recruitment from activation: Tyrobp mRNA was unchanged in activated resident microglia. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
  • Premisecitation

    In postmortem human brain tissue, dysregulation of microglial gene signatures is more common in female patients than in male patients.

    “Similar observations were made in a study of postmortem human brain tissue, where dysregulation of microglial gene signatures was shown to be more common in female patients than in male patients. 40”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [40] Coales I, Tsartsalis S, Fancy N, et al. Alzheimer's disease‐related transcriptional sex differences in myeloid cells. J Neuroinflammation. 2022; 19: 1‐ 13. 36199077 PMC9535846 source

      The Discussion reports that Bonham et al. inferred microglial-gene dysregulation in patients with Alzheimer’s disease to a greater extent in women than men. But this is a finding the cited paper attributes to another study; its own sex-specific gene-signature findings were primarily in postmortem microglia from donors without neurological disease, and its Results say the AD-donor samples showed no significant sex difference for the inflammatory gene sets tested. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • Findingown data

    M8 shows high expression of Lpl, a gene recently implicated in myelin-scavenging activated microglia.

    “M8 shows high expression of Lpl, a gene recently implicated in myelin‐scavenging activated microlia. 39”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [39] Bruce KD, Gorkhali S, Given K, et al. Lipoprotein lipase is a feature of alternatively‐activated microglia and may facilitate lipid uptake in the CNS during demyelination. Front Mol Neurosci. 2018; 11: 1‐ 13. 29599706 PMC5862862 source
  • Classified as probably not a substantial claim. 18
  • May combine two claims. 21
  • Classified as probably not a substantial claim.

    Premisecitation

    CellChat can predict the probability of 2021 validated molecular interactions between receptors and ligands across groups of cells.

    “CellChat can predict the probability of 2021 validated molecular interactions between receptors and ligands across groups of cells (Figure 5A–B).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [28] Jin S, Guerrero‐Juarez CF, Zhang L, et al. Inference and analysis of cell‐cell communication using CellChat. Nat Commun. 2021; 12: 1‐ 20. 33597522 PMC7889871 source
  • May combine two claims.

    Premisecitation

    Elevated PTN is detected in the substantia nigra of patients with Parkinson's disease and in the CSF of patients with AD.

    “Elevated PTN is detected in the substantia nigra of patients with Parkinson's disease and in the cerebrospinal fluid (CSF) of patients with AD. 41 , 42”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [41] Marchionini DM, Lehrmann E, Chu Y, et al. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007; 1147: 77‐ 88. 17368428 source
    • cites [42] Skillbäck T, Mattsson N, Hansson K, et al. A novel quantification‐driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Sci Rep. 2017; 7: 1‐ 12. 29042634 PMC5645330 source

      The Results (Validation of PTN 151–166 as a biomarker of AD; page unavailable) report elevated CSF levels in AD patients, supporting the AD portion of the sentence. The measured substance was the PTN 151–166 peptide, not full-length PTN; the paper does not establish elevated PTN in the substantia nigra of patients with Parkinson’s disease. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
  • May combine two claims.

    Premisecitation

    Microglial activation and actin remodeling are processes that can be mediated by Inpp5d.

    “which are both processes that can be mediated by Inpp5d. 6 , 20”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [6] Liu Q, Sasaki T, Kozieradzki I, et al. SHIP is a negative regulator of growth factor receptor‐mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999; 13: 786‐ 791. 10197978 PMC316591 source

      The paper’s Abstract (page unavailable) says PI3K and phospholipid-regulated signaling are implicated in cytoskeletal reorganization, and the SHIP-regulates-PKB section describes SHIP’s role in that signaling pathway. This provides indirect support for a connection to actin remodeling, but the paper does not show SHIP mediating actin remodeling or address microglial activation. (LLM, conf=0.73)

      Experimental — accuracy not yet measured
    • cites [20] Iguchi A, Takatori S, Kimura S, et al. INPP5D modulates TREM2 loss‐of‐function phenotypes in a β‐amyloidosis mouse model. iScience. 2023; 26: 106375. 37035000 PMC10074152 source
  • Classified as probably not a substantial claim.

    Premisecitation

    Astrocyte-derived PTN is an anti-inflammatory, neuroprotective factor secreted by reactive astrocytes.

    “Accumulating evidence points to astrocyte‐derived PTN as an anti‐inflammatory, neuroprotective factor secreted by reactive astrocytes. 43 , 44”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [43] Linnerbauer M, Lößlein L, Farrenkopf D, et al. Astrocyte‐derived pleiotrophin mitigates late‐stage autoimmune CNS inflammation. Front Immunol. 2022; 12: 1‐ 14. PMC8762329 35046956 source
    • cites [44] Iseki K, Hagino S, Mori T, et al. Increased syndecan expression by pleiotrophin and FGF receptor‐expressing astrocytes in injured brain tissue. Glia. 2002; 39: 1‐ 9. 12112370 source
  • May combine two claims.

    Premisecitation

    PSAP is secreted by microglia and astrocytes in humans and predominantly by microglia in mice.

    “PSAP is secreted by microglia and astrocytes in humans and predominantly by microglia in mice. 45 , 46”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [45] Zhang Ye, Chen K, Sloan SA, et al. An RNA‐sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014; 34: 11929‐ 11947. 25186741 PMC4152602 source

      The purification and RNA-Seq sections describe mouse cortical cell populations, but do not address PSAP secretion or compare its cellular sources in humans and mice. Searches for PSAP, prosaposin, and human–mouse glial secretion found no passage supporting the claim in our copy. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
    • cites [46] Zhang Ye, Sloan SA, Clarke LE, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016; 89: 37‐ 53. 26687838 PMC4707064 source

      The Results passages on human astrocyte transcriptomes and human–mouse functional differences do not address PSAP secretion or compare its cellular sources across species. Searches of our copy for “PSAP,” “prosaposin,” and secretion by microglia and astrocytes found no relevant passage; page numbers were not available. (LLM, conf=0.74)

      Experimental — accuracy not yet measured
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Previous studies of Inpp5d in AD have employed APP transgenic or knock-in models.

    “Previous studies of Inpp5d in AD have employed APP transgenic or knock‐in models to determine the effect of Inpp5d depletion on amyloid pathology. 18 , 19 , 20 , 49”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [18] Lin PB‐C, Tsai APo‐Yi, Soni D, et al. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2528‐ 2537. doi: 10.1002/alz.12849 36524682 source
    • cites [19] Castranio EL, Hasel P, Haure‐Mirande J‐V, et al. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2239‐ 2252. doi: 10.1002/alz.12821 36448627 PMC10481344 source
    • cites [20] Iguchi A, Takatori S, Kimura S, et al. INPP5D modulates TREM2 loss‐of‐function phenotypes in a β‐amyloidosis mouse model. iScience. 2023; 26: 106375. 37035000 PMC10074152 source
  • May combine two claims.

    Premisecitation

    In astrocytes, PSAP promotes motility and neuroprotective function, and is upregulated in the brains of patients with AD.

    “In astrocytes, it promotes motility and neuroprotective function, and is upregulated in the brains of patients with AD. 47 , 48”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [47] Liu B, Mosienko V, Vaccari Cardoso B, et al. Glio‐ and neuro‐protection by prosaposin is mediated by orphan G‐protein coupled receptors GPR37L1 and GPR37. Glia. 2018; 66: 2414‐ 2426. 30260505 PMC6492175 source

      The Results section on astrocyte motility reports that PSAP depletion slowed movement in a scratch assay, while the Results section on oxidative stress links PSAP signaling in astrocytes to protection of co-cultured neurons. The paper does not report PSAP upregulation in the brains of patients with AD; its reported increase was in culture media after neurons were stressed. Page numbers are unavailable in our copy. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [48] Mendsaikhan A, Tooyama I, Bellier J‐P, et al. Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology. Acta Neuropathol Commun. 2019; 7: 1‐ 26. PMC6925443 31864418 source

      The Results report increased PSAP protein in AD brain samples, and the Introduction describes PSAP as having neuroprotective properties. However, the paper does not report that PSAP promotes astrocyte motility or establish a neuroprotective function specifically in astrocytes; the Results find only limited PSAP staining in those cells. The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Castranio et al. observed increased amyloid plaque pathology at 6 to 6.5 months of age using immunohistochemistry despite no change in Aβ levels measured by ELISA.

    “They observed increased amyloid plaque pathology at 6 to 6.5 months of age using immunohistochemistry despite no change in Aβ levels measured by ELISA. 19”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [19] Castranio EL, Hasel P, Haure‐Mirande J‐V, et al. Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2239‐ 2252. doi: 10.1002/alz.12821 36448627 PMC10481344 source
  • Classified as probably not a substantial claim.

    Premisecitation

    Sex has effects on microglial morphology, gene expression, and function.

    “There is some precedent for sex having effects on microglial morphology, gene expression, and function. 33 , 34 , 35”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [33] Hanamsagar R, Alter MD, Block CS, Sullivan H, Bolton JL, Bilbo SD. Generation of a microglial developmental index in mice and in humans reveals a sex difference in maturation and immune reactivity. Glia. 2017; 65: 1504‐ 1520. 28618077 PMC5540146 source
    • cites [34] Guneykaya D, Ivanov A, Hernandez DP, et al. Transcriptional and translational differences of microglia from male and female brains. Cell Rep. 2018; 24: 2773‐ 2783. e6. 30184509 source
    • cites [35] Villa A, Gelosa P, Castiglioni L, et al. Sex‐specific features of microglia from adult mice. Cell Rep. 2018; 23: 3501‐ 3511. 29924994 PMC6024879 source
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Samuels et al. found that amyloid levels were not changed but microglial number and engagement with plaques increased.

    “Amyloid levels were not changed but microglial number and engagement with plaques increased.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [49] Samuels JD, Moore KA, Ennerfelt HE, et al. The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology. Alzheimer's Dement. 2023; 19(11): 1‐ 14. doi: 10.1002/alz.13089 PMC10576836 37061460 source
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Iguchi et al. provides evidence that Inpp5d loss increases glial engagement with plaques, as also observed by both Lin et al. and Samuels et al.

    “Iguchi et al. provides evidence that Inpp5d loss increases glial engagement with plaques, as also observed by both Lin et al. and Samuels et al.”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [20] Iguchi A, Takatori S, Kimura S, et al. INPP5D modulates TREM2 loss‐of‐function phenotypes in a β‐amyloidosis mouse model. iScience. 2023; 26: 106375. 37035000 PMC10074152 source
    • cites [18] Lin PB‐C, Tsai APo‐Yi, Soni D, et al. INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease. Alzheimer's Dement. 2023; 19(6): 2528‐ 2537. doi: 10.1002/alz.12849 36524682 source
    • cites [49] Samuels JD, Moore KA, Ennerfelt HE, et al. The Alzheimer's disease risk factor INPP5D restricts neuroprotective microglial responses in amyloid beta‐mediated pathology. Alzheimer's Dement. 2023; 19(11): 1‐ 14. doi: 10.1002/alz.13089 PMC10576836 37061460 source
  • May combine two claims.

    Findingown data

    In male mice, Inpp5d−/− is associated with a significant decrease in cell proportions in microglial cluster 1 (p = 0.0129), and Inpp5d+/− with a significant increase in microglial cluster 3 (p = 0.0323).

    “compared to wild‐type, there was a significant decrease in cell proportions from male Inpp5d−/− mice in microglial cluster 1 (p = 0.0129), and a significant increase in cell proportions from male Inpp5d+/− mice in microglial cluster 3 (p = 0.0323)”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    There are significant differences in the proportions of M1 (p = 4.4 × 10−3), M2 (p = 0.0348), and M3 (p = 8.4 × 10−3) microglia by sex.

    “we detected significant differences in the proportions of M1 (p = 4.4 × 10−3), M2 (p = 0.0348) and M 3 (p = 8.4 × 10−3) microglia”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    The eigenvalue of the Female-2 module also decreased in Inpp5d+/− endothelial cells, whereas the eigenvalue of the Female-3 module increased only in Inpp5d+/− astrocytes.

    “The eigenvalue of the Female‐2 module also decreased in Inpp5d +/− endothelial cells, whereas the eigenvalue of the Female‐3 module increased only in Inpp5d+/− astrocytes.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Findingown data

    There are overlaps in DEGs between male and female Inpp5d−/− mice (543 DEGs), between Inpp5d+/− and Inpp5d−/− in female mice (448 DEGs), and between Inpp5d+/− and Inpp5d−/− in male mice (388 DEGs).

    “there were overlaps in DEGs between male and female Inpp5d −/− mice (543 DEGs), Inpp5d +/− and Inpp5d −/− DEGs in female mice (448 DEGs), and Inpp5d +/− and Inpp5d −/− DEGs in male mice (388 DEGs)”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Each co-expression module was strikingly enriched in a particular cell type; the Female-1 module was highly expressed in microglia.

    “There was striking enrichment of each module in a particular cell type; for example, the Female‐1 module was highly expressed in microglia”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    In male Inpp5d−/− mice, there is a general increase in interaction strength, with the greatest increase in astrocytes and endothelial cells.

    “initially observed the opposite of what we observed in the female data set—a general increase in interaction strength in Inpp5d −/− mice, with the greatest increase occurring in astrocytes and endothelial cells (Figure S9).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Inferred ligand-receptor interactions from CellChat reflect actual cell-cell communication.
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    After correction for ambient RNA contamination, doublet inference and removal, and quality control, 57,742 cells were taken forward for analysis.

    “After correction for ambient RNA contamination, doublet inference and removal, and quality control (see Methods), 57,742 cells were taken forward for analysis”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Study design and conductown data

    The selective expression of Inpp5d in microglial clusters and the total loss of expression in Inpp5d−/− mice were confirmed.

    “We confirmed the selective expression of Inpp5d in microglial clusters and the small number of myeloid cells and erythrocytes present in our study (Figure S1), as well as the total loss of expression in Inpp5d −/− mice.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Cell viability was >94%.

    “Cell viability was >94%.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisenone given

    Castriano and Lin used regional spatial transcriptomics, which measure gene expression in regions of a slide-mounted sample rather than single cells.

    “Castriano and Lin used regional spatial transcriptomics. These technologies measure gene expression in regions of a slide‐mounted sample, rather than single cells.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    Samuels et al. performed a single-nucleus 3′-RNA-sequencing experiment with n = 3 biological replicates pooled into n = 1 technical replicate per genotype.

    “Samuels et al. performed a single‐nucleus 3′‐RNA‐sequencing experiment with n = 3 biological replicates pooled into n = 1 technical replicate per genotype.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationreasoning

    Due to differences across the four studies, it is difficult to draw firm conclusions on the role of Inpp5d in Alzheimer's pathology or compare these works with our own.

    “Due to the differences across these four studies, it is difficult to draw firm conclusions on the role of Inpp5d in Alzheimer's pathology or compare these works with our own.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Interpretationown data

    Decreases in PTN and increases in PSAP and VEGFA signaling may occur in both female and male Inpp5d−/− mice.

    “Taken together, these findings indicate that decreases in PTN and increases in PSAP and VEGFA signaling may occur in both female and male Inpp5d −/− mice”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Inferred ligand-receptor interactions from CellChat reflect actual cell-cell communication.
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationreasoning

    Cytoskeletal remodeling likely mediates chemotaxis, surveillance, and phagocytosis in microglia.

    “It seems likely that cytoskeletal remodeling would mediate chemotaxis, surveillance, and phagocytosis in microglia”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Study design and conductown data

    Sample size was reduced to n = 2 per genotype and sex, and variance across proportions in clusters M1 and M3 is high.

    “as our sample size was reduced to n = 2 per genotype and sex, and as variance across proportions in clusters M1 and M3 are high”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationreasoning

    Upregulation of PSAP expression in astrocytes and microglia may promote astrocyte reactivity and be neuroprotective.

    “These findings indicate that upregulation of PSAP expression in astrocytes and microglia may promote astrocyte reactivity and be neuroprotective.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Inferred ligand-receptor interactions from CellChat reflect actual cell-cell communication.
  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Premisenone given

    No study has modeled the effect of total loss of Inpp5d, as this leads to death before sufficient AD-like pathology has developed in mouse models.

    “No study has modeled the effect of total loss of Inpp5d, as this leads to death before sufficient AD‐like pathology has developed in mouse models.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationown data

    M1 cells seem to be redistributed, albeit not significantly, across M7 and M8.

    “and seem to be redistributed, albeit not significantly, across M7 and M8.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    Changes in the activity of these pathways based on sex and genotype could explain the changes observed in non-microglial cell types.

    “Changes in the activity of these pathways based on sex and genotype could explain the changes we observed in the non‐microglial cell types we discussed.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Inferred ligand-receptor interactions from CellChat reflect actual cell-cell communication.
  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationown data

    The dysregulated genes, otherwise masked by haplosufficiency of Inpp5d, will provide new leads for further investigating their roles in microglial function and neurodegenerative diseases.

    “The dysregulated genes, otherwise masked by haplosufficiency of Inpp5d, will provide new leads for further investigating their roles in microglial function and neurodegenerative diseases.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

    Premisenone given

    Our single-cell protocol enriches for microglia, whereas single-nucleus suspensions contain many neuronal nuclei with low numbers of microglia.

    “Our single‐cell protocol enriches for microglia, whereas single‐nucleus suspensions contain many neuronal nuclei with low numbers of microglia.”
    Quote in the paperNot a substantial claim
32 of 32
  • The paper relies on this without support.

    Wild-type mouse brain transcriptomes are a valid model for human brain before Alzheimer's disease pathology.

    “This study design with wild‐type mice is a critical step in understanding the function of Inpp5d without the confounding effect of amyloid pathology on cell transcriptomes, as is the case in humans before AD pathology starts.”
  • The paper relies on this without support.

    Loss of Inpp5d function is the mechanism by which INPP5D variants affect Alzheimer's disease risk.

    “Inpp5d is genetically associated with Alzheimer's disease risk. Loss of Inpp5d alters amyloid pathology in models of amyloidosis.”
    “Although previous work has focused on reducing the expression of Inpp5d in mouse models of amyloid, we aimed to determine the effects of both partial and total Inpp5d loss on the brain transcriptome”
  • The paper relies on this without support.

    Inferred ligand-receptor interactions from CellChat reflect actual cell-cell communication.

    “CellChat can predict the probability of 2021 validated molecular interactions between receptors and ligands across groups of cells (Figure 5A–B).”
  • The paper relies on this without support.

    Co-expression modules identified by hdWGCNA correspond to biologically meaningful cell states.

    “hdWGCNA is an unsupervised method of identifying groups of genes associated with cell states.”
  • The paper relies on this without support.

    Mouse Inpp5d loss effects are relevant to human INPP5D in Alzheimer's disease.

    “Given the increasing evidence that microglia play a critical role in AD pathogenesis 30 and that Inpp5d is exclusively expressed in microglia, we believe that our data will be invaluable resources for the research community for designing future experiments.”
5 of 5

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Inpp5d expression is described as both exclusive and nonexclusive to microglia

    Minor

    The results say Inpp5d is expressed exclusively in microglia, but earlier report its expression in myeloid cells and erythrocytes as well.

  • Male cluster changes are assigned to the female panel

    Minor

    The results cite Figure 2A for changes in male mice, but the figure caption identifies panel A as female data and panel B as male data.

  • Figure 5D is cited for gene modules but depicts signaling

    Minor

    The cited panel concerns incoming and outgoing signaling interactions, not gene-module preservation.

3 of 3

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Dabin, L. C., Kersey, H., Kim, B., Acri, D. J., Sharify, D., Lee‐Gosselin, A., Lasagna‐Reeves, C. A., Oblak, A. L., Lamb, B. T., & Kim, J.
Affiliations
  • Indiana University Indianapolis (US)
  • Department of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA
Corresponding author
Kim, Jungsu
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2024-06-26
Volume
20
Issue
8
Pages
5311-5323
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4400046482
Cited by
10
References
51
Citations by year
2026: 6 · 2025: 2 · 2024: 2
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
Funders
  • National Institutes of Health (R01AG077829, R01AG071281, R21AG072738, RF1AG074543)
  • Lilly Endowment
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords
INPP5D, Alzheimer's disease risk
MeSH terms
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Alzheimer Disease, Animals, Brain, Disease Models, Animal, Female, Male, Neuroglia, Sex Factors, Microglia, Mice, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-17.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-17.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review